Intermediate-dose cyclophosphamide and granulocyte colony-stimulating factor is a valid alternative to high-dose cyclophosphamide for mobilizing peripheral blood CD34+ cells in patients with multiple myeloma

Acta Haematologica

Volumn 109, Issue 4, 2003, Pages 184-188

  Petrucci, Maria Teresa ^a   Avvisati, Giuseppe ^a   La Verde, Giacinto ^a   De Fabritiis, Paolo ^a   Ribersani, Michela ^a   Palumbo, Giovanna ^a   De Felice, Lidia ^a   Rusignuolo, Alessandra ^a   Simone, Francesca ^a   Meloni, Giovanna ^a   Mandelli, Franco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cyclophosphamide; Multiple myeloma; Peripheral blood progenitor cell mobilization

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MESNA; PREDNISONE; SARCOLYSIN; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL COUNT; CELL ISOLATION; CELL MOTILITY; CONTROLLED STUDY; DRUG FATALITY; DRUG FEVER; DRUG MEGADOSE; FEMALE; HEALTH ECONOMICS; HEMATOPOIETIC CELL; HEMORRHAGIC CYSTITIS; HOSPITALIZATION; HUMAN; HUMAN CELL; HYDRATION; LEUKAPHERESIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUTROPENIA; PATIENT CARE; PERIPHERAL BLOOD STEM CELL; PNEUMONIA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDNISONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0038649206     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000070967     Document Type: Article

References (17)

1. Barlogie B: Toward a cure for multiple myeloma? N Engl J Med 1991;325:1304-1306.
2. Juttner CA, To LB, Roberts MM: Comparison of hematological recovery, toxicity and supportive care of autologous PBSC, autologous BM and allogeneic BM transplant. Int J Cell Cloning 1992;10:160-164.
3. Vesico RA, Han EJ, Schiller GJ, Lee JC, Wu CH, Chao J, Shin J, Kim A, Lichtenstein AK, Berenson JR: Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts. Bone Marrow Transplant 1996;18:103-110.
4. 2 in patients with advanced cancer. Aust NZ J Med 1992;22:660-665.
5. Attal M, Payen C, Facon T, Michaux JL, Guilhot F, Monconduit M, Fuzibet JG, Caillot D, Dorvaux V, Harousseau JL, Cahn JY, Grosbois B, Stoppa AM, Ifrah N, Sotto JJ, Pignon B, Battaille R: Single versus double transplant in myeloma: A randomized trial of the Intergroupe français du Myélome (IFM). Blood 1997;90:418a.
6. Demuynck H, Delforge M, Verhoef G, Zachee P, Vandenberghe P, Boogaeerts M: Comparative study of peripheral progenitor cell collection in patients with multiple myeloma after single-dose cyclophosphamide combined with rhGM-CSF or rhG-CSF. Br J Haematol 1995;90:384-392.
7. Tricot G, Gazitt Y, Leemhuis T, Jagannath S, Desikan KR, Siegel D, Fassas A, Tindle S, Nelson J, Juttner C, Tsukamoto A, Hallagan J, Alkinson T, Reading C, Hoffman R, Barlogie B: Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. Blood 1998;91:4489-4495.
8. Lenhard RE, Oken MM, Barnes JM, Humphrey RL, Glick JH, Silverstein MN: Highdose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma. Cancer 1984;53:1456-1460.
9. To LB, Shepher KM, Haylock DN, Dyson PG, Charles P, Thorp DL, Dale BM, Dart GW, Roberts MM, Sage RE: Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol 1990;18:442-447.
10. Siena S, Bregni M, Brando B, Belli N, Ravagnani F, Gandola L, Stern AC, Lanodorp PM, Bonadonna G, Gianni AM: Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991;77:400-409.
11. Rowly SD, Bensinger WI, Golley TA, Buckner CD: Effect of cell concentration on bone marrow and peripheral blood stem cell cryopreservation. Blood 1994;83:2731-2736.
12. Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L, Cheson B, Crowley J, Barlogie B: Peripheral blood stem cell transplant for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients. Blood 1995;85:588-596.
13. Haas R, Mohle R, Fruhauf S, Goldschmidt H, Witt B, Flentje M, Wannemacher M, Hunstein W: Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994;12:3787-3794.
14. Bensinger WI, Longing K, Appelbaum F, Rowley S, Weaver C, Lilleby K, Gooley T, Lynch M, Higano T, Klarnet J, Chauncey T, Storb R, Buckner CD: Peripheral blood stem cells collected after recombinant granulocyte colony stimulating factor: An analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994;87:825-831.
15. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, West W: An analysis of engraftment kinetics as a function of the CD34+ content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995;86:3961-3969.
16. 2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 1996;17:691-697.
17. Goldschmidt H, Hegenbart U, Wallmeier M, Hohans S, Haas R: Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor. Br J Haematol 1997;98:736-744.